Docs Who Lift

Docs Who Lift
undefined
Nov 19, 2026 • 26min

Should You Be Worried About the GLP-1 Blindness Warning?

The FDA’s new NAION warning on GLP-1 medications has sparked plenty of alarm. This discussion explores what NAION is, how sleep apnea, blood pressure, and anatomy may factor in, and why the evidence remains uncertain. It also covers ophthalmology guidance on eye exams, the difference between a warning and a recall, and the sudden vision-loss symptom that demands immediate care.
undefined
19 snips
Nov 3, 2026 • 29min

The Truth About BPC-157 & Peptides (3 Doctors Discuss)

Leigh Baxt, a translational scientist trained at Stanford, Harvard, and Brown, unpacks viral claims about FDA-approved peptides. She explains the difference between relaxed compounding enforcement and actual drug approval, then explores the arduous path from molecule to medicine. The conversation tackles patents, “natural” safety claims, weak international evidence, clinical-trial fine print, testimonials, and the long-term cancer risks that may take decades to emerge.
undefined
17 snips
Oct 26, 2026 • 54min

The Menopause Misinformation Problem with Amanda Thebe

Amanda Thebe, menopause educator, patient advocate, coach, and author of The Menopocalypse, shares her turbulent path to a perimenopause diagnosis. She discusses hormone therapy that worsened her symptoms, finding effective nonhormonal care, and the online misinformation targeting women. The conversation explores testosterone hype, supplements, compounded drugs, pellets, and venture-funded telehealth clinics, while championing evidence-based, individualized care.
undefined
36 snips
Oct 7, 2026 • 58min

Retatrutide & Beyond: Eli Lilly Exec on Next-Gen GLP-1s

Ken Custer, Eli Lilly’s cardiometabolic chief and a longtime drug-development leader, discusses what comes after tirzepatide. The conversation explores phase 3 retatrutide results, amylin combinations, complementary brain pathways, tolerability, and preserving muscle during weight loss. It also tackles pricing, insurance coverage, clinical-trial challenges, prevention, industry transparency, and the risks of gray-market treatments.
undefined
37 snips
Sep 22, 2026 • 49min

Food Noise Is Real, and Now We Can Measure It

Dr. Emily Dhurandhar, an obesity researcher focused on appetite and patient-centered measurement, and Dr. David Allison, an obesity researcher and biostatistician, explore the science of food noise. They discuss how patient experiences with GLP-1 medications sparked research, how food noise differs from hunger and cravings, and the questionnaire designed to measure it. They also examine clinical relevance, quality-of-life benefits, future studies, and claims that pharma invented the term.
undefined
38 snips
Aug 30, 2026 • 48min

Does Metabolically Healthy Obesity Even Exist?

Christian Rodriguez, an obesity researcher at Pennington Biomedical, studies metabolically healthy and extreme obesity. He discusses why definitions of metabolically healthy obesity vary and often do not hold up. He compares new obesity frameworks, previews a rare study of people with BMI ≥60, and tackles GLP-1 stigma and the importance of early treatment.
undefined
14 snips
Aug 3, 2026 • 40min

Is Your Obesity Genetic? Food Noise and Bardet-Biedl Syndrome Explained

Dr. Jesse Richards, a researcher-clinician at the University of Oklahoma studying genetic and syndromic obesity, explains Bardet-Biedl syndrome and how it can make the brain feel starved. He describes clear physical signs, a simple BMI × food-noise screening math trick, and why standard diets or weight-loss shots often fail while targeted medicines can reset hunger signaling.
undefined
Jul 7, 2026 • 37min

PCOS Renamed to PMOS? Here's Why and What Changes for You

Susan Bryant, clinician and Instagram health educator, brings clinical clarity on the proposed rename from PCOS to PMOS. They unpack diagnostic criteria, the confusing Rotterdam phenotypes, and why insulin resistance matters. Conversation covers how treatments like metformin, GLP-1s, birth control, and inositol are being used and the tradeoffs around changing the name and patient identity.
undefined
21 snips
Jun 17, 2026 • 57min

Are Peptides the New Snake Oil? What the Actual Science Says With Barbell Medicine

Dr. Jordan Feigenbaum, co‑founder of Barbell Medicine and strength-training MD, and Dr. Austin Baraki, chemist‑clinician from Barbell Medicine, cut through peptide hype. They explain what peptides are, why 'natural' does not mean safe, the role of GLP-1 in normalizing injectables, missing human trials for popular peptides, and proposals for faster, safer study and quality control.
undefined
23 snips
Jun 8, 2026 • 45min

Retatrutide Phase 3 Results: What the Data Actually Means

David W, a nurse practitioner and Triumph 1 participant, shares firsthand trial experience and concise incretin/glucagon expertise. He describes adding glucagon to GLP-1/GIP, notable weight loss and side-effect timeline. They discuss dramatic metabolic improvements, cardiometabolic markers, functional gains like less knee pain and sleep apnea, and how results compare to bariatric outcomes.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app